(Q42168234)

English

Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development

scientific article published on July 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Statins potentiate the in vitro anti-hepatitis C virus activity of selective hepatitis C virus inhibitors and delay or prevent resistance development (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

4

object named as

Pieter Leyssen

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

object named as

Jan Paeshuyse

2

0 references

object named as

Johan Neyts

9

0 references

1

object named as

Leen Delang

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

3

object named as

Inge Vliegen

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

5

object named as

Susan Obeid

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

author name string

Fabien Zoulim

7

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Anne Op de Beeck

8

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

language of work or name

0 references

publication date

1 July 2009

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

50

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

6-16

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

Clinical consequences of hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Selective inhibitors of hepatitis C virus replication

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Reliance of host cholesterol metabolic pathways for the life cycle of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Statins inhibit HIV-1 infection by down-regulating Rho activity.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Role of simvastatin and methyl-β-cyclodextin on inhibition of poliovirus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Hydroxymethyl-glutaryl coenzyme a reductase inhibition limits cytomegalovirus infection in human endothelial cells

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Antiviral activity of lovastatin against respiratory syncytial virus in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Different anti-HCV profiles of statins and their potential for combination therapy with interferon

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Targeting lipid metabolism in the treatment of hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Disruption of hepatitis C virus RNA replication through inhibition of host protein geranylgeranylation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Comparative In Vitro Anti-Hepatitis C Virus Activities of a Selected Series of Polymerase, Protease, and Helicase Inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Differential antiviral activity of derivatized dextrans

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

A three-dimensional model to analyze drug-drug interactions

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Antiviral drugs that target cellular proteins may play major roles in combating HIV resistance.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Atorvastatin does not exhibit antiviral activity against HCV at conventional doses: a pilot clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Fluvastatin inhibits hepatitis C replication in humans

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Modelling how ribavirin improves interferon response rates in hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Disposition of fluvastatin, an inhibitor of HMG-COA reductase, in mouse, rat, dog, and monkey

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

The safety of statins in clinical practice

1 reference

https://api.crossref.org/works/10.1002%2FHEP.22916

21 January 2018

Identifiers

10.1002/HEP.22916

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42168234&oldid=1935115994"